Sickle Cell Disease
📧 Sign up to get email alerts when something new happens for Sickle Cell Disease.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-08-21EMA Suspended: Oxbryta (voxelotor) — Pfizer Europe MA EEIG
The EMA suspended Oxbryta (voxelotor) for treating sickle cell disease-related anemia.
-
CLINICAL_TRIALS withdrawal · 2026-04-09Clinical Trial Update: Biotin-Acridine Red Cell Exchange Kinetics [Phase 2]
A Phase 2 trial of Biotin-Acridine for sickle cell disease has been withdrawn. The study was sponsored by Cerus Corporation.
-
CLINICAL_TRIALS withdrawal · 2026-04-03Clinical Trial Update: A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy [Phase 2]
A Phase 2 trial of Mitapivat in participants with sickle cell disease and nephropathy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-03-25Clinical Trial Update: Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype [Phase 3]
A Phase 3 trial evaluating a single dose of Exa-cel for severe sickle cell disease (βS/βC genotype) has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-01-22Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years [Phase 1]
Phase 1 study evaluating oral GSK4172239D versus placebo in adults with sickle cell disease was terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2025-10-17EMA confirms suspension of sickle cell disease medicine Oxbryta
EMA has suspended Oxbryta (voxelotor) for sickle cell disease after trials showed a higher rate of death and disease complications, so the b…
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) [Phase 3]
A Phase 3 trial evaluating thromboprophylaxis in sickle cell disease patients with central venous catheters has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-10-24Clinical Trial Update: Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies [EARLY_Phase 1]
The Early Phase 1 trial investigating pre-transplant immunosuppression and donor stem cell transplantation for severe hemoglobinopathies has…
-
EMA withdrawal · 2024-10-08EMA Suspended: Oxbryta (voxelotor) — Pfizer Europe MA EEIG
The EMA has suspended the EU marketing authorization for Oxbryta (voxelotor) by Pfizer Europe MA EEIG, affecting its use for sickle cell dis…
-
CLINICAL_TRIALS withdrawal · 2024-08-09Clinical Trial Update: Voxelotor Brain Oxygenation and Neurocognitive Study [Phase 4]
Pfizer-sponsored Phase 4 study evaluating voxelotor for brain oxygenation and neurocognitive outcomes in sickle cell disease has been withdr…
-
EMA withdrawal · 2023-09-29EMA Revoked: Adakveo (Crizanlizumab) — Novartis Europharm Limited
EMA has revoked Adakveo (crizanlizumab) marketed by Novartis Europharm Limited for sickle cell disease/anemia.
-
EMA withdrawal · 2023-05-26Revocation of authorisation for sickle cell disease medicine Adakveo
The European Medicines Agency revoked the authorisation for Adakveo (crizanlizumab) for the treatment of sickle cell disease in the EU.
-
CLINICAL_TRIALS withdrawal · 2020-07-15Clinical Trial Update: Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. [Phase 3]
A Phase 3 pediatric trial evaluating ticagrelor versus placebo for reducing vaso-occlusive crises in sickle cell disease was withdrawn.
-
EMA withdrawal · 2020-02-11EMA Application withdrawn: Xyndari — Emmaus Medical Europe Ltd
EMA withdrew the application for Xyndari by Emmaus Medical Europe Ltd in the orphan medicine program for anemia and sickle cell disease.
-
CLINICAL_TRIALS withdrawal · 2018-09-26Clinical Trial Update: Ketamine Sickle Cell Disease [Phase 3]
A Phase 3 clinical trial evaluating ketamine for sickle cell disease and chronic pain has been withdrawn from the study list.
-
CLINICAL_TRIALS withdrawal · 2018-07-26Clinical Trial Update: Risk Factors for Allo-immunization in Sickle Cell Disease
The clinical trial NCT03401125 investigating risk factors for allo-immunization in sickle cell disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-16Clinical Trial Update: A Phase Ib Study of NVX-508 in Sickle Cell Disease [Phase 1]
The Phase Ib trial of NVX-508 in sickle cell disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-05Clinical Trial Update: Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease [Phase 1]
Phase 1 clinical trial of imatinib and carvedilol for pulmonary hypertension in adults with sickle cell disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-06-21Clinical Trial Update: A Study of Oral L-citrulline in Sickle Cell Disease [Phase 1]
A Phase 1 clinical trial of oral L-citrulline for sickle cell disease has been withdrawn, halting any further enrollment.
-
CLINICAL_TRIALS withdrawal · 2018-06-21Clinical Trial Update: A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease [Phase 1]
A Phase 1 pilot trial evaluating azithromycin prophylaxis to prevent acute chest syndrome in sickle cell disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-05-24Clinical Trial Update: Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients
A clinical trial evaluating SANGUINATE for sickle cell disease has been withdrawn. The document summarizes safety and pharmacokinetics consi…
-
CLINICAL_TRIALS withdrawal · 2017-10-18Clinical Trial Update: Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study [Phase 2]
This Phase 2 feasibility trial of risk-based therapy for sickle cell disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-03-24Clinical Trial Update: Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC) [Phase 2]
A Phase 2 trial comparing patient-controlled analgesia versus bolus narcotic therapy for vaso-occlusive crisis in sickle cell disease was wi…
-
CLINICAL_TRIALS withdrawal · 2017-01-19Clinical Trial Update: Androgen Regulation of Priapism in Sickle Cell Disease [EARLY_Phase 1]
This document announces the withdrawal of an early-phase trial investigating androgen regulation of priapism in sickle cell disease.
-
CLINICAL_TRIALS withdrawal · 2016-12-23Clinical Trial Update: Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study
An exploratory trial evaluating exhaled carbon monoxide as a marker of hemolysis in sickle cell disease has been withdrawn. The sponsor is U…